SCHEMBL8101019

SCHEMBL8101019

CCCCCCCCCCC(CCO)C(=O)NCC(O)CNC(=O)C(CCO)CCCCCCCCCC

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 8/20 0.42
CA2 P00918 1/20 0.42
FFAR1 O14842 2/20 0.41
FFAR4 Q5NUL3 1/20 0.41
FAAH O00519 1/20 0.41
PSMD14 O00487 2/20 0.41
PLA2G1B P04054 2/20 0.41
MMP2 P08253 2/20 0.41
ATG4B Q9Y4P1 2/20 0.41
HSP90AA1 P07900 1/20 0.41
RAD52 P43351 1/20 0.41
BIRC2 Q13490 1/20 0.40
LCK P06239 1/20 0.40
PPARD Q03181 1/20 0.40
ZDHHC20 Q5W0Z9 1/20 0.40
ZDHHC2 Q9UIJ5 1/20 0.40
MMP1 P03956 2/20 0.39
MMP3 P08254 2/20 0.39
MMP9 P14780 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5063316 1.00 GPR84 (0.42) GPR84CA2FFAR1FFAR4FAAH
SCHEMBL2374648 1.00 GPR84 (0.42) GPR84CA2FFAR1FFAR4FAAH
SCHEMBL8109186 0.92 FAAH (0.46) FFAR1FFAR4FAAH
SCHEMBL29205058 0.89 CA2 (0.41) GPR84CA2FFAR1PSMD14PLA2G1B
SCHEMBL29205059 0.89 CA2 (0.41) GPR84CA2FFAR1PSMD14PLA2G1B
SCHEMBL29205057 0.89 CA2 (0.41) GPR84CA2FFAR1PSMD14PLA2G1B
SCHEMBL8109755 0.85 USP2 (0.48) CA2BIRC2
SCHEMBL8109149 0.85 USP2 (0.48) CA2BIRC2
SCHEMBL8108513 0.83 GNAI3 (0.50) CA2BIRC2
SCHEMBL8109579 0.83 GNAI3 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12514806-B2 Cosmetic composition comprising ceramides and sphingolipid CRODA KOREA LTD. (KR) 2026-01-06 US disclosed
US-20240225987-A9 LIQUID CRYSTAL COMPOSITION INCLUDING CERAMIDE AND METHOD OF PREPARING THE SAME CRODA KOREA LTD (KR) 2024-07-11 US disclosed
US-20240173240-A1 COSMETIC COMPOSITION COMPRISING CERAMIDES AND SPHINGOLIPID CRODA KOREA LTD (KR) 2024-05-30 US disclosed
CN-117942280-A Liquid crystal composition comprising ceramide and preparation method thereof 禾大韩国有限公司 2024-04-30 CN disclosed
CN-117942279-A Cosmetic composition comprising ceramide and sphingolipid 禾大韩国有限公司 2024-04-30 CN disclosed
US-20240130950-A1 LIQUID CRYSTAL COMPOSITION INCLUDING CERAMIDE AND METHOD OF PREPARING THE SAME CRODA KOREA LTD (KR) 2024-04-25 US disclosed
EP-4356898-A1 COSMETIC COMPOSITION COMPRISING CERAMIDES AND SPHINGOLIPID Croda Korea Limited (KR) 2024-04-24 EP disclosed
EP-4356895-A1 LIQUID CRYSTAL COMPOSITION INCLUDING CERAMIDE AND METHOD OF PREPARING THE SAME Croda Korea Limited (KR) 2024-04-24 EP disclosed
US-11166899-B2 Composition for external application containing a ceramide, a derivative thereof and an extract of Hibisci cortex AMOREPACIFIC CORPORATION (KR) 2021-11-09 US disclosed
US-20200179260-A1 COMPOSITION FOR EXTERNAL APPLICATION CONTAINING A CERAMIDE, A DERIVATIVE THEREOF AND AN EXTRACT OF HIBISCI CORTEX AMOREPACIFIC CORPORATION (KR) 2020-06-11 US disclosed
US-6060612-A SKIN CARE COSMETIC PACIFIC CORPORATION (KR) 2000-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11166899-B2 Composition for external application containing a ceramide, a derivative thereof and an extract of Hibisci cortex CERT1, CERS2, SGMS1 GPR84 3449/4885CA2 3130/4885FFAR1 1991/4885
US-20200179260-A1 COMPOSITION FOR EXTERNAL APPLICATION CONTAINING A CERAMIDE, A DERIVATIVE THEREOF AND AN EXTRACT OF HIBISCI CORTEX CERT1, CERS2, SGMS1 GPR84 3449/4885CA2 3130/4885FFAR1 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.